Stayble Therapeutics presented at Swedish Shareholders´ Association´s event Aktiedagen Stockholm 2022

Stayble Therapeutics' CEO Andreas Gerward gave a presentation on 14 March 2022 at Aktiedagen Stockholm 2022, an event arranged by Swedish Shareholders´ Association´s.

CEO Andreas Gerward presented the Company, the development of the injection treatment STA363 for degenerative disc disease and gave a general update on the ongoing clinical phase 2b-trial.

The presentation from March 14 is available at: https://youtu.be/yevDh5o0WgI

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se